Rare Neurological Disease Treatment Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The Rare Neurological Disease Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Rare Neurological Disease Treatment Market:

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

According to The Business Research Company’s Rare Neurological Disease Treatment Global Market Report 2024, The rare neurological disease treatment market size has grown strongly in recent years. It will grow from $8.98 billion in 2023 to $9.79 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to biosimilars in rare disease treatment, globalization of clinical trials, healthcare reimbursement policies, orphan drug designations, advancements in genetic research.

The rare neurological disease treatment market size is expected to see strong growth in the next few years. It will grow to $13.41 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to improved diagnostic tools, precision medicine advancements, patient-centric drug development, integration of real-world evidence, telemedicine for patient support, shift towards personalized therapies. Major trends in the forecast period include technological innovations, ai in drug discovery, blockchain for data security, machine learning in drug discovery.

The prevalence of rare neurological diseases is expected to propel the growth of the rare neurological disease treatment market going forward. Rare neurological diseases refer to low-prevalence neurological disorders, including Huntington’s disease, ALS (amyotrophic lateral sclerosis), Rett syndrome, and various forms of muscular dystrophy. Treating rare neurological diseases involves multiple approaches to manage symptoms, slow disease progression, and improve the quality of life for individuals affected by these conditions. For instance, in January 2023, according to an article published by BioMed Central Ltd., a UK-based publisher of open-access scientific journals, the collective prevalence of Rett syndrome was determined to be 7.1 per 100,000 females in a combined sample size of 9.57 million women, with a total of 673 confirmed cases. Therefore, the prevalence of rare neurological diseases is driving the growth of the rare neurological disease treatment market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=12146&type=smp

The rare neurological disease treatment market covered in this report is segmented –

1) By Drug Type: Biologics, Small Molecules

2) By Therapy: Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Cyberknife, Other Therapies

3) By Mode Of Administration: Oral, Injectable, Other Modes Of Administration

4) By Disorders: Aicardi Syndrome, Aicardi-Goutières Syndrome, Reflex Sympathetic Dystrophy Syndrome, Battaglia-Neri Syndrome, Creutzfeldt Jakob Disease, Agnosia, Other Disorders

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Drug Store, Online Pharmacies

The development of orphan pharmaceuticals is a key trend gaining popularity in the rare neurological disease treatment market. Major companies operating in the rare neurological disease treatment sector are focused on developing innovative and specialized treatments to strengthen their position in the market. For instance, in April 2023, Orphalan SA, a French orphan drug development company, introduced Cuvrior, a novel trientine tetrahydrochloride (TETA-4HCl), in the European market. Cuvrior is now commercially available for treating adult patients with stable Wilson disease who have undergone copper reduction therapy and have shown tolerance to D-penicillamine. The drug received approval from the United States Food and Drug Administration (FDA) and was granted orphan drug exclusivity (ODE) in April 2022 for this specific patient population.

The rare neurological disease treatment market report table of contents includes:

Executive Summary
Rare Neurological Disease Treatment Market Characteristics
Rare Neurological Disease Treatment Market Trends And Strategies
Rare Neurological Disease Treatment Market – Macro Economic Scenario
Global Rare Neurological Disease Treatment Market Size and Growth

Global Rare Neurological Disease Treatment Market Competitive Benchmarking
Global Rare Neurological Disease Treatment Market Competitive Dashboard
Key Mergers And Acquisitions In The Rare Neurological Disease Treatment Market
Rare Neurological Disease Treatment Market Future Outlook and Potential Analysis
Appendix

Top Major Players: